| Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts TK Karikari, TA Pascoal, NJ Ashton, S Janelidze, AL Benedet, ... The Lancet Neurology 19 (5), 422-433, 2020 | 817 | 2020 |
| Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology NJ Ashton, TA Pascoal, TK Karikari, AL Benedet, J Lantero-Rodriguez, ... Acta neuropathologica 141, 709-724, 2021 | 367 | 2021 |
| Microglial activation and tau propagate jointly across Braak stages TA Pascoal, AL Benedet, NJ Ashton, MS Kang, J Therriault, M Chamoun, ... Nature medicine 27 (9), 1592-1599, 2021 | 292 | 2021 |
| A multicentre validation study of the diagnostic value of plasma neurofilament light NJ Ashton, S Janelidze, A Al Khleifat, A Leuzy, EL van der Ende, ... Nature communications 12 (1), 3400, 2021 | 271 | 2021 |
| Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline J Lantero Rodriguez, TK Karikari, M Suárez-Calvet, C Troakes, A King, ... Acta neuropathologica 140, 267-278, 2020 | 250 | 2020 |
| Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative TK Karikari, AL Benedet, NJ Ashton, J Lantero Rodriguez, A Snellman, ... Molecular psychiatry 26 (2), 429-442, 2021 | 230 | 2021 |
| Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ … M Suárez‐Calvet, TK Karikari, NJ Ashton, J Lantero Rodriguez, ... EMBO molecular medicine 12 (12), e12921, 2020 | 229 | 2020 |
| Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum AL Benedet, M Milà-Alomà, A Vrillon, NJ Ashton, TA Pascoal, F Lussier, ... JAMA neurology 78 (12), 1471-1483, 2021 | 227 | 2021 |
| The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease J Simrén, A Leuzy, TK Karikari, A Hye, AL Benedet, J Lantero‐Rodriguez, ... Alzheimer's & Dementia 17 (7), 1145-1156, 2021 | 204 | 2021 |
| Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease A Moscoso, MJ Grothe, NJ Ashton, TK Karikari, JL Rodríguez, A Snellman, ... JAMA neurology 78 (4), 396-406, 2021 | 171 | 2021 |
| Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease M Milà-Alomà, NJ Ashton, M Shekari, G Salvadó, P Ortiz-Romero, ... Nature medicine 28 (9), 1797-1801, 2022 | 170 | 2022 |
| Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum A Moscoso, MJ Grothe, NJ Ashton, TK Karikari, JL Rodriguez, A Snellman, ... Brain 144 (1), 325-339, 2021 | 158 | 2021 |
| An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders NJ Ashton, A Hye, AP Rajkumar, A Leuzy, S Snowden, M Suárez-Calvet, ... Nature Reviews Neurology 16 (5), 265-284, 2020 | 152 | 2020 |
| Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes MM Mielke, RD Frank, JL Dage, A Jeromin, NJ Ashton, K Blennow, ... JAMA neurology 78 (9), 1108-1117, 2021 | 134 | 2021 |
| Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring NJ Ashton, S Janelidze, N Mattsson-Carlgren, AP Binette, O Strandberg, ... Nature medicine 28 (12), 2555-2562, 2022 | 130 | 2022 |
| Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility TK Karikari, NJ Ashton, G Brinkmalm, WS Brum, AL Benedet, ... Nature Reviews Neurology 18 (7), 400-418, 2022 | 126 | 2022 |
| Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration A Benussi, TK Karikari, N Ashton, S Gazzina, E Premi, L Benussi, ... Journal of Neurology, Neurosurgery & Psychiatry 91 (9), 960-967, 2020 | 121 | 2020 |
| Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70 A Keshavan, J Pannee, TK Karikari, JL Rodriguez, NJ Ashton, ... Brain 144 (2), 434-449, 2021 | 107 | 2021 |
| Biomarker modeling of Alzheimer’s disease using PET-based Braak staging J Therriault, TA Pascoal, FZ Lussier, C Tissot, M Chamoun, G Bezgin, ... Nature aging 2 (6), 526-535, 2022 | 105 | 2022 |
| Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease P Chatterjee, S Pedrini, NJ Ashton, M Tegg, K Goozee, AK Singh, ... Alzheimer's & Dementia 18 (6), 1141-1154, 2022 | 104 | 2022 |
Pedro Rosa-NetoProfessor, McGill UniversityVerified email at mcgill.ca
